Supplementary Figure Legends:
Supplementary Figure S1: Peptide array screen to identify the FGFR1 sequence that binds hNedd4-1.
A) Sequence of FGFR1 cytosolic region that bound hNedd4-1 (which was spotted on the original proteome array (Persaud et al, 2009) ). Red asterisk highlights the beginning of the kinase domain, while the VLLVRPSR sequence is underlined with a blue line. (B) Peptide array sequences that cover the FGFR1 cytosolic region, including 3 positive controls (PY motifs from known Nedd4 interactors: LAPTM5, CNrasGEF, ENaC). (C) Peptide array screen with purified hNedd4-1, identifying 3 putative binding regions (spots number 11-12, 17-19, 61-63) , which we named peptide 1, 2 & 3, respectively. Positive controls (PY motifs) are marked. Figure S2 : Lack of binding of peptide 2 to rat Nedd4-1 or human Nedd4-2.
Supplementary
A) His-tagged FGFR1-C terminus (Cterm) immobilized on NTA-agarose beads, or NTA beads alone (negative control), was incubated with purified rat Nedd4-1 (rNedd4-1) and blotted with anti Nedd4-1 antibodies (upper panel). B) As in panel A, only purified human Nedd4-2 (hNedd4-2) was used for binding and immunoblotted with anti Nedd4-2 antibodies.
In both panels A and B, binding of immobilized GST-CNrasGEF to Nedd4 proteins was used as a positive control: Sup = supernatant. Middle and bottom panels are controls for the amounts of proteins used for the assay, as in Fig 1A. (C) FP assay to measure affinity of interaction of hNedd4-2 WW3 domain with peptide 2 (the VL***PSR peptide), revealing no binding. Binding of this WW3 domain to a PY motif from ENaC (Kd=4.1 M) was used as a positive control. Figure S3 : Deletion of the hNedd4-1 binding site on FGFR1 leads to loss of FGFR1 ubiquitylation and to its sustained activation and stabilization.
(A) Deletion of 3 core residues (VLx) from the FGFR1 peptide 2 region (FGFR1-3) leads to a reduction in hNedd4-1 binding to the mutant receptor and substantial loss of receptor ubiquitylation: Hek293T cells were transfected (tfxn) with GFP-FGFR1(WT) or FGFR1-3, along with V5-hNedd4-1 (WT or catalytically inactive CS mutant). Cells were lysed and lysate either subjected to immunoprecipitation (IP) with GFP antibody (FGFR1) and immunoblotted for hNedd4-1 (middle panel), or boiled in SDS, immunoprecipitated with anti GFP antibody and the extent of FGFR1 ubiquitylation analyzed with anti ubiquitin (Ub) antibody. Lower panels depict the amount of FGFR1/ FGFR1-3 immunoprecipitated (3 rd panel), and the amount of hNedd4-1 (WT or CS) in the lysates (lowest panel) used for the experiment. Mixed lysate (of FGFR1 and hNedd4-1 transfected separately into different cells/plates) represent an added control for the co-IP, to ensure that binding did not take place after cell lysis. (B) Deletion of 6 core residues (VLxxxP) from the FGFR1 peptide 2 region (FGFR1-6) leads to a ablation of hNedd4-1 binding to the mutant receptor and complete loss of receptor ubiquitylation. The experiment was performed exactly as in panel A. (C) Ligand-dependent binding of hNedd4-1 to FGFR1 and FGFR1 ubiquitylation: Hek293T cells were transfected as in A, treated with FGF2 (+heparin) for the indicated times, and the extent of FGFR1 ubiquitylation (upper panel) or activation (2 nd panel) analyzed. Lower 3 panels are controls for levels of total FGFR1 in the IP, hNedd4-1 in the lysate and loading (actin). (D) Stabilization of FGFR1-6: GFP-tagged FGFR1 WT or the 6 mutant expressed in HeLa cells were serum-starved and stimulated with FGF2(+heparin) for the indicated times, cells lysed and proteins in the lysates separated on 8%SDS-PAGE and immunoblotted for GFP (FGFR1) or actin. Note the disappearance of the upper band (arrow) over time in the WT FGFR1, but its stabilization in the FGFR1-6 mutant. This upper band represents the cell-surface pool of FGFR1, based on our previous work. Figure S4 : Cbl knockdown does not affect stability of active FGFR1, and normal binding of FGFR1-6 to FRS2 and PLC .
(A) Knockdown of both cCbl and CblB with siRNA in HeLa cells has no effect on stability of activated (Tyr-phosphorylated) FGFR1: Cells were transfected with GFP-tagged FGFR1 and incubated with siRNAs for cCbl and CblB. FGFR1 was then subjected to IP with anti GFP antibodies (FGFR1) and blotted with anti pTyr or GFP antibodies. Lower 3 panels are controls for loading (actin), and for demonstration of knockdown of cCbl and CblB. (B) Activated FGFR1-6 can bind its substrates FRS2 and PLC : HeLa cells were transfected with GFPtagged FGFR1-WT, 6 or the kinase inactive (KI) mutants. Cells were serum-starved and then stimulated (or not) with FGF2(+heparin) for 5 min, and co-IP (and Tyr phosphorylation) of their targets FRS2 and PLC analyzed. Note similar co-IP of these substrates between WT and the 6 mutant, but not with the kinase inactive mutant.
Supplementary Figure S5: Impaired endocytosis of FGFR1-6.
Time course of ligand-induced endocytosis of (A) GFP-FGFR1-WT or (B) GFP-FGFR1-6 and their bound ligand (FGF2-Biotin+Streptavidin Cy3), as detailed in Fig 4B. (C) Intracellular accumulation of FGF2 in HeLa cells expressing GFP-FGFR1-WT or GFP-FGFR1-6. Cells were pulsed with FGF2-Biotin on ice, followed by Streptavidin Cy5 incubation. Cells were then incubated at 37 o C for the indicated timepoints followed by acid stripping to remove remaining Cells were then lysed, hNedd4-1 immunoprecipitated and co-IP of FGFR3 or FGFR1 analyzed, as indicated. Note that while both FGFR1 and FGFR3 are activated (as evident from their activation of Akt (pAkt)), only FGFR1, but not FGFR3, can bind hNedd4-1. (C) Maternally deposited zNedd4a (zNedd4-1) transcript in early stage embryos. Zebrafish zNedd4a transcript was detected in 1-cell stage, 8-cell stage, and 1000-cell stage embryos (prior to onset of zygotic transcription), following reverse transcriptase PCR from total RNA samples. The transcript size is 794 base pairs. DNA standard, 100bp ladder. 
Supplementary Table:

Supplementary Materials and Methods
Antibodies, reagents, cell lines and transfections
The following Antibodies were used in this study: Akt (#9272), pSer473-Akt (#9271) from Cell (Sun et al, 2008) . Transfection of neuronal stem cells was achieved using the Amaxa nucleofector device and corresponding mouse neuronal stem cells kit (#VPG-1004).
cDNA constructs
Human FGFR1 cDNA (AC#BC015035) was sub-cloned into pcDNA6.2emGFP using the Gateway system (Invitrogen). The deletion mutants hFGFR1-3-GFP (439-441), hFGFR1-6-GFP (439-444) and hFGFR1-KI-GFP (Y653F/Y654F, kinase inactive (Mohammadi et al, 1996)) were created using a Site Directed Mutagenesis kit (Qiagen) with WT hFGFR1-GFP in pcDNA6.2emGFP as template. Zebrafish FGFR1was amplified from Zebrafish cDNA library using primers designed against the 5' and 3' ends of zFGFR1 (NM_152962). zFGFR1 cDNA was cloned into pDONR221 (Invitrogen) and then sub-cloned into the expression vector pCSDEST2-GFP (Invitrogen) using the Gateway system. zFGFR1-6 (424-429) was created using Site Directed Mutagenesis kit. Zebrafish Nedd4a WW3 (a.a.429-467) was amplified from the pDONR221-zFGFR1 template and zNedd4L WW3 was created by mutating residues T500S and K501R in hNedd4-2 WW3 domain (a.a.476-514). Both zNedd4a and zNedd4L WW3 domains were subcloned into the bacterial expression vector pETMHtb.
Purification of epitope tagged and fusion proteins for in-vitro experiments
hFGFR1 C terminus residues 399-616 (in pQE30), hNedd4-1 WW1, WW2, WW3, WW4 domains (in pQE30), hNedd4-1 Hect domain (in pGEX6p-1) and hNedd4-2 WW3 domain (in pQE30) were expressed in E.coli strain BL21 (RIL) as described (Persaud et al, 2009 ). Proteins were purified from 100 ml of growth medium using either glutathione-sepharose resin (for GST tagged proteins) or Ni 2+ NTA resin (for 6xHis tagged proteins) and eluted using either 80 mM reduced glutathione (Amersham Biosciences) or 80 mM Imidazole (Sigma), respectively. The C terminus of CNrasGEF (PY motif containing protein and a known substrate for Nedd4 (Pham & Rotin, 2001) ), hNedd4-1, hNedd4-2 and rNedd4-1 were also purified as described (Persaud et al, 2009 ).
In-vitro binding experiments
All binding reactions were conducted at 4°C in PBS supplemented with 1 mM DTT for 2h.
Purified 6xHis-hFGFR1 C terminus (residues 399-616) (0.5 g) and GST-CNrasGEF C terminus (0.5 g) immobilized on Ni 2+ NTA and glutathione-sepharose resin, respectively, was incubated with purified hNedd4-1, hNedd4-2 or rNedd4-1 (0.5 g). Biotinylated peptides 1, 2, 3 and ENaC PY motif peptide (10 g) immobilized on streptavidin agarose were incubated with 10 g purified hNedd4-1, and to detect binding of peptide 2 to hNedd4-1 domains, biotinylated peptide 2 (10 g) immobilized on streptavidin agarose was incubated with 10 g of purified hNedd4-1 6xHis WW1, WW2, WW3, WW4 or GST-Hect domains. For the reciprocal experiment, the hNedd4-1 domains were precipitated using either glutathione-sepharose or Ni 2+ NTA beads and binding to biotinylated peptide 2 was determined. In addition, biotinylated zebrafish peptide 2 (10 g) immobilized on streptavidin agarose was incubated with 10 g purified zNedd4a or zNedd4L 6xHis-GST-WW3 domains to detect binding to these domains;
binding of hFGFR1 peptide 2 (10 g) to hNedd4-1 6xHis-GST-WW3 domains was used as a positive control. All samples were washed (x2) with HNTG (50 mM HEPES (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, 10% glycerol). Binding was detected by immunoblotting with anti-hNedd4-1, anti-hNedd4-2, anti-rNedd4-1, anti-6xHis, or anti-GST antibodies or by using streptavidin-HRP, as indicated.
Peptide Array Screens
Peptide arrays were printed on derivatized membranes (Amino-peg 500 -UC540 sheet; Intavis, 32- 
